Montelukast in allergic rhinitis: a systematic review and meta-analysis.
Allergic rhinitis is common. This systematic review outlines the evidence regarding montelukast in allergic rhinitis and provides a meta-analysis of its efficacy. The evidence suggests that montelukast does reduce nasal symptom score by 3.4% (95% CI: 2.5% to 4.2%) when compared with placebo. Montelukast is not as effective as topical nasal steroids or antihistamines and should therefore be regarded as second line therapy. When used, montelukast should be used in combination with an antihistamine.
Grainger
J
J
Department of Otorhinolaryngology, University Hospital Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK. joegrainger@fsmail.net
Drake-Lee
A
A
D000085:Acetates / Q000627:therapeutic use*; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D011788:Quality of Life; D011804:Quinolines / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D013440:Sulfides; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000085:Acetates; D000305:Adrenal Cortex Hormones; D003521:Cyclopropanes; D006634:Histamine H1 Antagonists; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast